Brokerages back Astral's demerger strategy but warn that rising competition, weaker PVC prices and execution risks could weigh on earnings in the near term
Maruti Suzuki rallies on strong PV demand, market share gains and easing supply woes, though analysts remain watchful of El Niño's impact on rural demand
Asahi tie-up, India growth, Africa expansion and new categories such as dairy, energy drinks and snacks are expected to diversify Varun Beverages' revenues and support long-term growth
Aggressive store additions, category diversification and an expected recovery in like-for-like growth are expected to support Trent's long-term growth plans
Nirmal Bang believes the company's margin leadership is structural rather than cyclical
Since 2007, the company has made investments of ₹4,900 crore across 135 startups across sectors
Analysts see opportunities from localisation and backward integration, but warn that intense competition, thin margins and execution risks could weigh on returns
RIL stock will re-rate on a continuous basis as key milestones of transition are achieved, starting with the JIO IPO and subsequently the commissioning of 10 GW integrated solar project, analysts said
The stock advanced 7% over the past month, outperforming the Nifty 50
At current price, company is trading at a steep 47 times its FY27 earnings
Notably, JLR, a part of Tata Motors, said that it is targeting medium-term double-digit revenue growth and increase focus on the North America market.
RIL's annual report, according to CLSA, highlights the company's ambition to leverage AI offerings, plans to expand data centre capacity, along with progress in new energy.
Coforge aims to double revenue to $5 billion by FY30, banking on Encora integration, large deals and AI-led growth to sustain momentum
Brokerages see strategic benefits from HCL Tech's investment in Sarvam, though long-term returns will depend on the AI firm's ability to scale and execute effectively
Systematix has maintained a 'Hold' rating on Nestle India, valuing the stock at FY28E P/E of 65x for a target price of ₹1,460.
Improving revenue mix, along with higher capital efficiency, UBS believes, could support a structural re-rating of the stock towards premium asset management and wealth management multiples
The stock delivered higher returns than the benchmark Nifty Pharma over the past year
Kumiai Chemical's earnings revision highlights strong demand for pyroxasulfone, but concerns over generic competition and weak earnings growth keep analysts cautious on PI Industries
Foray into green energy, data centres and reducing dependence on the oil & gas business augur well for Reliance Industries, says G Chokkalingam founder of Equinomics Research.
IndiGo, in its recently held analyst meet, reiterated its ambition to raise international capacity share to around 40 per cent by FY30 from the current 30 per cent, according to a note by Elara.